All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The 60th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from 1–4 December 2018. On Saturday 1 December 2018, an oral abstract session was held entitled: 722. Clinical Allogeneic Transplantation: Acute and Chronic GvHD, Immune Reconstitution: GvHD Grading and Outcomes and Management. During this session, Abstract #69 was presented, entitled: Metabolomics Profiling after Allogeneic Hematopoietic Stem Cell Transplantation Unravels a Specific Signature in Human Acute GvHD by David Michonneau from Hôpital Saint-Louis AP-HP, Paris, France.
Many previous researches were assessing acute graft-versus-host disease (GvHD) pathophysiology but only a few of them focused on human GvHD. Recent studies have shown the role of tissue microenvironment or host microbiota regarding allo-immune responses. The focus of this study was to find metabolomics alterations associated with allogeneic transplantation and to define a pathway.
This study shows that allogeneic transplantation causes major metabolomics changes in recipients, which may associate with drug intakes, metabolic stress or microbiota alteration. Complex lipid metabolism and amino acid metabolites play an important role in GvHD development. Dr. Michonneau added that “this study highlights the potential role of circulating metabolites in GvHD pathophysiology that could be targeted for prophylaxis or treatment.”
Subscribe to get the best content related to GvHD delivered to your inbox